Compare VRA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | TLSA |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.6M | 124.0M |
| IPO Year | 2010 | 2017 |
| Metric | VRA | TLSA |
|---|---|---|
| Price | $3.47 | $1.00 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 104.6K | ★ 534.3K |
| Earning Date | 06-10-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $416,097,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $0.87 |
| 52 Week High | $4.39 | $2.53 |
| Indicator | VRA | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 42.55 |
| Support Level | $2.97 | $0.87 |
| Resistance Level | $3.46 | $1.45 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 7.41 | 38.07 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.